Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin + metformin vs pioglitazone + metformin after short-term intensive insulin therapy in newly diagnosed type 2 diabetes mellitus
ChiCTR2300078750Phase 4Not yet recruiting
- Sponsor
- Luzhou People's Hospital
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Henagliflozin + metformin with pioglitazone + metformin (2 arms). Primary endpoints: HOMA-IR and HOMA-β. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
henagliflozinmetforminpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2300078750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078750.